SCHEMBL2294239

SCHEMBL2294239

COC(=O)C(NC(=O)c1csc(-c2ccc(NC(=O)Nc3ccc(F)cc3F)cc2)n1)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 5/20 0.55
LMNA P02545 2/20 0.55
DGAT1 O75907 2/20 0.51
SMN1; SMN2 Q16637 5/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
MAPT P10636 2/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
PSMD14 O00487 1/20 0.44
HTT P42858 2/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
ROCK1 Q13464 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294244 1.00 CSGALNACT1 (0.55) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2298568 0.91 CSGALNACT1 (0.66) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2298564 0.91 CSGALNACT1 (0.66) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2301345 0.88 CSGALNACT1 (0.52) CSGALNACT1LMNASMN1; SMN2MAPTMEN1
SCHEMBL2301342 0.88 CSGALNACT1 (0.52) CSGALNACT1LMNASMN1; SMN2MAPTMEN1
SCHEMBL2301334 0.83 DGAT1 (0.52) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2301344 0.83 DGAT1 (0.52) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2293820 0.82 DGAT1 (0.54) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2293823 0.82 DGAT1 (0.54) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A
SCHEMBL2293740 0.80 MAPK1 (0.58) CSGALNACT1LMNADGAT1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT CSGALNACT1 455/4885LMNA 3819/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.